On November 10, 2022 Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies that are safe and accessible to cancer patients, reported the presentation of activity and efficacy preclinical data for AB-101 with several combinations of therapeutic monoclonal antibodies in multiple preclinical models of cancer (Press release, Artiva Biotherapeutics, NOV 10, 2022, View Source [SID1234623660]). The data were presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 37TH Annual Meeting in Boston.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These data provide additional support for the use of AB-101 as a highly scaled, off-the-shelf, ADCC-enhancing NK cell product candidate with optimized cellular profile but without the need for genetic modification," said Peter Flynn, Ph.D., cofounder and Chief Operating Officer of Artiva. "Specifically, these data support the use of AB-101 to enhance ADCC activity when combined with antibodies such as Rituxan, Gazyva, Erbitux and Herceptin, highlighting the broad therapeutic potential of AB-101."

The data presented highlight the use of Artiva’s AlloNKTM platform to generate NK cells with high and consistent expression of the high affinity variant of the receptor CD16 as well as other receptors involved in anti-tumor activity including NKG2D, DNAM-1, NKp30, and NKp46, all without the requirement to engineer the underlying NK cells. The resulting cryopreserved, off-the-shelf cell therapy candidate AB-101 combined with therapeutic monoclonal antibodies was seen to drive anti-tumor cell activity in a variety of solid tumor and hematopoietic model systems. Artiva is conducting a Phase 1/2 clinical trial (ClinicalTrials.gov Identifier: NCT04673617) to assess the safety and clinical activity of AB-101 alone and in combination with the anti-CD20 monoclonal antibody, rituximab. Artiva is also developing a combination therapy comprised of AB-101 and Affimed N.V.’s Innate Cell Engager AFM13 for treatment of patients with relapsed/refractory CD30-positive lymphomas.

The abstract is available on the Journal for ImmunoTherapy of Cancer website: View Source The poster is available for viewing by SITC (Free SITC Whitepaper) attendees on the SITC (Free SITC Whitepaper) virtual platform: View Source

The poster can also be viewed here.

About AB-101

AB-101 is a cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers. Artiva selects cord blood units with the high affinity variant of the receptor CD16 and a KIR-B haplotype for enhanced product activity. Artiva can generate thousands of doses of pure, cryopreserved, infusion-ready NK cells from a single umbilical cord blood unit while retaining the high and consistent expression of CD16 without the need for engineering. Artiva is conducting a Phase 1/2 multicenter clinical trial (ClinicalTrials.gov Identifier: NCT04673617) to assess the safety and clinical activity of AB-101 alone and in combination with the anti-CD20 monoclonal antibody, rituximab, in patients with relapsed or refractory B-cell-non-Hodgkin lymphoma (NHL) who have progressed beyond two or more prior lines of therapy. Artiva is also developing a combination therapy comprised of AB-101 and Affimed N.V.’s Innate Cell Engager AFM13 for treatment of patients with relapsed/refractory CD30-positive lymphomas.